Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals Inc. | BCX9930 - (REDEEM-1) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Trial Discontinued | Oral | Hematology |
| Biodexa Pharmaceuticals plc | eRapa (rapamycin, sirolimus) - (Serenta) | Familial Adenomatous Polyposis (FAP) | Phase 3 | Enrollment Initiation | oral | Genetic Disorder |
| Biodexa Pharmaceuticals plc | Tolimidone | Type 2 diabetes | Phase 2a | Ongoing | Oral | Endocrinology |
| Biodexa Pharmaceuticals plc | eRapa (rapamycin, sirolimus) | Non-muscle Invasive Bladder Cancer | Phase 2 | Ongoing | oral | Oncology |
| Biofrontera Inc. | Ameluz (BF-200 ALA) | Actinic Keratosis | Phase 3 | Topical | N/A | |
| Biofrontera Inc. | Ameluz and BF-RhodoLED XL | Actinic keratosis on the extremities, neck and trunk | sNDA Filing | Data Released | Topical | Oncology |
| Biofrontera Inc. | Ameluz (BF-200 ALA) | Basal cell carcinoma | Phase 3 | Enrollment Conclusion | Topical | Oncology |
| Biofrontera Inc. | Ameluz with BF-RhodoLED | Acne | Phase 2b | Topical | N/A |
